News
RGEN
178.20
-0.04%
-0.07
Repligen (RGEN) Stock Looks Reasonable Despite Its 35% Five Year Fall
Simply Wall St · 18h ago
Baron SMID Cap ETF Q3 2026 Contributors And Detractors
Seeking Alpha · 1d ago
Analysts Offer Insights on Healthcare Companies: Repligen (RGEN), OmniAb (OABI) and Incyte (INCY)
TipRanks · 2d ago
Analysts Offer Insights on Healthcare Companies: ProMIS Neurosciences (PMN), OmniAb (OABI) and Repligen (RGEN)
TipRanks · 2d ago
RBC Capital Remains a Buy on Repligen (RGEN)
TipRanks · 2d ago
William Blair refreshes stock Conviction List with 5 additions, 3 removals
Seeking Alpha · 2d ago
Weekly Report: what happened at RGEN last week (1026-1030)?
Weekly Report · 2d ago
Repligen–BioLife Deal Faces Market, Integration, and Regulatory Risks That Could Undermine Synergies and Long-Term Value
TipRanks · 3d ago
Repligen announces $1 Billion private convertible senior notes transaction
Seeking Alpha · 5d ago
Repligen Announces New Convertible Notes and Capital Restructuring
TipRanks · 5d ago
Repligen Announces $1 Bln Convertible Notes Offering To Extend Debt Maturity
NASDAQ · 5d ago
Repligen to issue $1B of 0.25% Convertible Senior Notes due 2031
TipRanks · 5d ago
Repligen To Issue $1B Of 0.25% Convertible Senior Notes Due 2031 As Part Of Exchange, With ~$541.4M Of New Notes Issued In Exchange For ~$456.8M Of 2028 Notes And ~$458.6M Of New Notes Issued For Cash
Benzinga · 5d ago
Can Repligen (RGEN) Justify Its Price As Raised Guidance Lifts Sentiment?
Simply Wall St · 5d ago
Conestoga Micro Cap Composite: Q3 2026 Leaders, Laggards, Buys And Sells
Seeking Alpha · 6d ago
KeyBanc Reaffirms Their Buy Rating on Repligen (RGEN)
TipRanks · 6d ago
Why Repligen Stock Is Up 5.1% And What's Next After Record Revenue
Simply Wall St · 10/29 01:21
Repligen Is Maintained at Outperform by RBC Capital
Dow Jones · 10/28 16:15
Analysts Are Bullish on These Healthcare Stocks: Repligen (RGEN), Benitec Biopharma (BNTC)
TipRanks · 10/28 15:11
Repligen price target raised to $200 from $185 at RBC Capital
TipRanks · 10/28 12:50
More
Webull provides a variety of real-time RGEN stock news. You can receive the latest news about Repligen through multiple platforms. This information may help you make smarter investment decisions.
About RGEN
Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. Its franchises include filtration, chromatography, process analytics and proteins. Its filtration franchise includes product offering covering upstream and downstream technologies. Its filtration products include XCell Alternating Tangential Flow (ATF) Cell Retention Systems, Flat Sheet Cassettes, Hollow Fiber Consumables, Tangential Flow Filtration Systems and Fluid Management. Its chromatography franchise includes products used in downstream purification, development, manufacturing and quality control of biological drugs. Its chromatography franchise includes OPUS Pre-Packed Columns, KRM Chromatography Systems and other additional chromatography products. Its process analytics include Downstream process analytical technology (PAT) and Upstream PAT. Its Proteins include Protein A Affinity Ligands, AVIPure Resins for New Modalities and Growth Factors.